ArticleHaematologica2026
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Anna J T Smit et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
2026
this papercites it